The Efficacy and Safety of the Combination of Sacubitril Valsartan Sodium Tablets and Metoprolol Succinate Sustained-Release Tablets in the Treatment of Coronary Heart Disease with Chronic Heart Failure
Objective Exploring the efficacy and safety of sacubitril valsartan sodium tablets and metoprolol succinate sustained-release tablets in patients with coronary heart disease(CHD)and chronic heart failure(CHF).Methods Selecting 60 patients with coronary heart disease complicated with chronic heart failure admitted to our hospital from August 2022 to March 2023 as the research subjects,divide into a control group and an observation group according to the random number table method.The control group(n=30)was given metoprolol succinate sustained-release tablets,and the observation group(n=30)was given metoprolol succinate sustained-release tablets and sacubitril valsartan sodium tablets.Clinical efficacy,cardiac function,N-terminal brain natriuretic peptide precursor(NT-proBNP)and adverse effects were compared between the two groups.Results After treatment,the total effective rate of the observation group was 96.67%,which was higher than the control group's 73.33%,the difference between groups was statistically significant(P﹤0.05);the observation group had higher levels of stroke output and left ventricular ejection fraction compared to the control group,the left ventricular end diastolic diameter was shorter than that of the control group,and NT-proBNP level was lower than that in the control group,the differences between groups were statistically significant(P﹤0.05).Comparison of adverse reactions between two groups,there was no statistically significant difference between groups(P﹥0.05).Conclusion Treatment of patients with coronary heart disease combined with chronic heart failure using sacubitril valsartan sodium tablets and metoprolol succinate sustained-release tablets,and the effect was definite,which can help improve the cardiac function and reduce NT-proBNP level,and it is relatively safe and worthy of promotion.